-
Je něco špatně v tomto záznamu ?
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases
V. Ručilová, A. Świerczek, D. Vanda, P. Funk, B. Lemrová, A. Gawalska, A. Bucki, B. Nowak, M. Zadrożna, K. Pociecha, M. Soural, E. Wyska, M. Pawłowski, G. Chłoń-Rzepa, P. Zajdel
European journal of medicinal chemistry.
2021 ;
209 (-) :
112854.
[pub] 20200919
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
Perzistentní odkaz
https://www.medvik.cz/link/bmc21019522
- MeSH
- antiflogistika chemie farmakokinetika farmakologie terapeutické užití MeSH
- autoimunitní nemoci farmakoterapie MeSH
- cyklické nukleotidfosfodiesterasy, typ 7 antagonisté a inhibitory MeSH
- imidazoly chemie farmakokinetika farmakologie terapeutické užití MeSH
- inhibitory fosfodiesteras chemie farmakokinetika farmakologie terapeutické užití MeSH
- inhibitory fosfodiesterasy 4 chemie farmakokinetika farmakologie terapeutické užití MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední BALB C MeSH
- potkani Wistar MeSH
- pyridiny chemie farmakokinetika farmakologie terapeutické užití MeSH
- zánět farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Herein, we describe the rapid synthesis of a focused library of trisubstituted imidazo[4,5-b]pyridines and imidazo[4,5-c]pyridines from 2,4-dichloro-3-nitropyridine using the combination of solution-phase/solid-phase chemistry as new potential anti-inflammatory agents in the treatment of autoimmune diseases. Structure-activity relationship studies, followed by the structure optimization, provided hit compounds (17 and 28) which inhibited phosphodiesterase 4 (PDE4) with IC50 values comparable to rolipram and displayed different inhibitory potency against phosphodiesterase 7 (PDE7). Among them, compound 17 showed a beneficial effect in all the studied animal models of inflammatory and autoimmune diseases (concanavalin A-induced hepatitis, lipopolysaccharide-induced endotoxemia, collagen-induced arthritis, and MOG35-55-induced encephalomyelitis). In addition, compound 17 showed a favorable pharmacokinetic profile after intraperitoneal administration; it was characterized by a fast absorption from the peritoneal cavity and a relatively long terminal half-life in rats. It was found to penetrate brain barrier in mice. The performed experiments sheds light on the impact of PDE7A inhibition for the efficacy of PDE4 inhibitors in these disease conditions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019522
- 003
- CZ-PrNML
- 005
- 20210830101115.0
- 007
- ta
- 008
- 210728s2021 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2020.112854 $2 doi
- 035 __
- $a (PubMed)33022582
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Ručilová, Veronika $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00, Olomouc, Czech Republic; Palacký University, Faculty of Science, Department of Organic Chemistry, 17 listopadu 12, 771 46, Olomouc, Czech Republic
- 245 10
- $a New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases / $c V. Ručilová, A. Świerczek, D. Vanda, P. Funk, B. Lemrová, A. Gawalska, A. Bucki, B. Nowak, M. Zadrożna, K. Pociecha, M. Soural, E. Wyska, M. Pawłowski, G. Chłoń-Rzepa, P. Zajdel
- 520 9_
- $a Herein, we describe the rapid synthesis of a focused library of trisubstituted imidazo[4,5-b]pyridines and imidazo[4,5-c]pyridines from 2,4-dichloro-3-nitropyridine using the combination of solution-phase/solid-phase chemistry as new potential anti-inflammatory agents in the treatment of autoimmune diseases. Structure-activity relationship studies, followed by the structure optimization, provided hit compounds (17 and 28) which inhibited phosphodiesterase 4 (PDE4) with IC50 values comparable to rolipram and displayed different inhibitory potency against phosphodiesterase 7 (PDE7). Among them, compound 17 showed a beneficial effect in all the studied animal models of inflammatory and autoimmune diseases (concanavalin A-induced hepatitis, lipopolysaccharide-induced endotoxemia, collagen-induced arthritis, and MOG35-55-induced encephalomyelitis). In addition, compound 17 showed a favorable pharmacokinetic profile after intraperitoneal administration; it was characterized by a fast absorption from the peritoneal cavity and a relatively long terminal half-life in rats. It was found to penetrate brain barrier in mice. The performed experiments sheds light on the impact of PDE7A inhibition for the efficacy of PDE4 inhibitors in these disease conditions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x chemie $x farmakokinetika $x farmakologie $x terapeutické užití $7 D000893
- 650 _2
- $a autoimunitní nemoci $x farmakoterapie $7 D001327
- 650 _2
- $a cyklické nukleotidfosfodiesterasy, typ 7 $x antagonisté a inhibitory $7 D054708
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imidazoly $x chemie $x farmakokinetika $x farmakologie $x terapeutické užití $7 D007093
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a inhibitory fosfodiesterasy 4 $x chemie $x farmakokinetika $x farmakologie $x terapeutické užití $7 D058988
- 650 _2
- $a inhibitory fosfodiesteras $x chemie $x farmakokinetika $x farmakologie $x terapeutické užití $7 D010726
- 650 _2
- $a pyridiny $x chemie $x farmakokinetika $x farmakologie $x terapeutické užití $7 D011725
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Świerczek, Artur $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmacokinetics and Physical Pharmacy, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Vanda, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00, Olomouc, Czech Republic; Palacký University, Faculty of Science, Department of Organic Chemistry, 17 listopadu 12, 771 46, Olomouc, Czech Republic
- 700 1_
- $a Funk, Petr $u Palacký University, Faculty of Science, Department of Organic Chemistry, 17 listopadu 12, 771 46, Olomouc, Czech Republic
- 700 1_
- $a Lemrová, Barbora $u Palacký University, Faculty of Science, Department of Organic Chemistry, 17 listopadu 12, 771 46, Olomouc, Czech Republic
- 700 1_
- $a Gawalska, Alicja $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Bucki, Adam $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Nowak, Barbara $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmacobiology, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Zadrożna, Monika $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmacobiology, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Pociecha, Krzysztof $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmacokinetics and Physical Pharmacy, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Soural, Miroslav $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00, Olomouc, Czech Republic; Palacký University, Faculty of Science, Department of Organic Chemistry, 17 listopadu 12, 771 46, Olomouc, Czech Republic
- 700 1_
- $a Wyska, Elżbieta $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmacokinetics and Physical Pharmacy, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Pawłowski, Maciej $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Chłoń-Rzepa, Grażyna $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688, Kraków, Poland
- 700 1_
- $a Zajdel, Paweł $u Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688, Kraków, Poland. Electronic address: pawel.zajdel@uj.edu.pl
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 209, č. - (2021), s. 112854
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33022582 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101115 $b ABA008
- 999 __
- $a ok $b bmc $g 1690364 $s 1139968
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 209 $c - $d 112854 $e 20200919 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20210728
